Nektar Therapeutics Now Covered by Cowen and Company (NKTR)
Stock analysts at Cowen and Company assumed coverage on shares of Nektar Therapeutics (NASDAQ:NKTR) in a report issued on Thursday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating and a $17.00 price target on the stock. Cowen and Company’s target price suggests a potential upside of 27.72% from the stock’s previous close.
Shares of Nektar Therapeutics (NASDAQ:NKTR) opened at 13.31 on Thursday. Nektar Therapeutics has a 52 week low of $5.65 and a 52 week high of $13.80. The stock’s 50-day moving average is $11.99 and its 200-day moving average is $10.90. The company’s market cap is $1.541 billion.
Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Thursday, August 8th. The company reported ($0.37) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.44) by $0.07. The company had revenue of $33.86 million for the quarter, compared to the consensus estimate of $26.22 million. The company’s quarterly revenue was up 43.0% on a year-over-year basis. On average, analysts predict that Nektar Therapeutics will post $-1.11 earnings per share for the current fiscal year.
A number of other firms have also recently commented on NKTR. Analysts at Brean Capital raised their price target on shares of Nektar Therapeutics (NASDAQ:NKTR) from $14.00 to $17.00 in a research note to investors on Thursday, August 15th. They now have a “buy” rating on the stock. Analysts at MKM Partners raised their price target on shares of Nektar Therapeutics (NASDAQ:NKTR) from $13.00 to $14.00 in a research note to investors on Thursday, June 20th. They now have a “buy” rating on the stock.
One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $13.83.
Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.